Drug Profile
MK 6186
Alternative Names: MK-6186Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antibacterials; Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in HIV-1-infections in Germany (PO, Tablet)